For decades, cancer immunotherapy has focused primarily on CD8 + cytotoxic T lymphocytes as the main executors of tumor cell killing. However, growing clinical and single-cell sequencing evidence ...
Researchers found that lowering MHC I can expose cancerous or foreign cells to CD4+ T cell attack, reshaping assumptions ...
CD4/CD8 T-cell ratios in the renal interstitium significantly mediate the association between peripheral blood CD4+/CD8+ T-cell ratios and lupus nephritis therapeutic outcomes. Peripheral and renal ...
This study analyzed lung infections in immunocompromised patients admitted to the ICU and explored how different levels of CD4⁺T-cell depletion are associated with pathogen distribution and ...
Phase I study to evaluate the safety and efficacy of switchable CAR-T cell therapy with FY001 and CART001 in patients with refractory CD20-positive B-cell non-Hodgkin lymphoma (EPOC1803). CD4 ≥124.5 ...
Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with longer PFS, suggesting T-cell composition may serve as a biomarker to ...
Hope for adults and children with cancers Camilla Jandus' team is currently preparing a clinical trial of TCR-engineered CD4-based cell therapy. The trial will include different types of cancer ...
Among women with HIV infection, both lower CD4 counts and higher HIV RNA viral load were associated with higher incidence rates of moderate and severe cervical dysplasia, carcinoma in situ, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results